MOSAIC: 2 Mix and Match COVID-19 Vaccines + Boosters
Participants needed: Ages 30+
Mix and match of the COVID-19 vaccine doses for SAfety and ImmunogeniCity
If you are interested in participating in MOSAIC, or have questions, please email firstname.lastname@example.org
Start Date: December 2021
MOSAIC-2 will evaluate a third (3rd) dose of an authorized COVID-19 vaccine in adults (booster shots). You do not need to have participated in MOSAIC-1 to join MOSAIC-2. If you were in MOSAIC-1 you can join MOSAIC-2.
In MOSAIC-2 we will evaluate the safety, tolerability, and immune response (protection) to a third dose of a COVID-19 vaccine currently authorized in Canada (either the Pfizer-BIONTech or Moderna mRNA vaccine) in people who had two doses of COVID-19 vaccines at least six months ago.
If you received AstraZeneca as your first or second dose, you may participate in the study. AstraZeneca is not being given as part of this study.
This study will be looking to answer questions critical to public health such as:
- How much protection is provided and how long does that protection last if you receive two different vaccines for your first and second COVID-19 vaccine doses
- What is the safety and effectiveness if different COVID-19 vaccine products are used for the 3rd dose?
Am I eligible to participate?
You may be able to participate if:
- You are 30+ years old and in good health
- You are available for all the study visits.
- You are in good health with stable health conditions.
- You are not pregnant.
- You have a record of first two doses of the authorized COVID-19 vaccines you received.
You do not need to have participated in MOSAIC-1 to join MOSAIC-2. If you were in MOSAIC-1 you can join MOSAIC-2.
There are other study criteria that will be reviewed at the first visit to determine if you are eligible or not.
What will you be asked to do?
You will have 4 clinic visits and 1 telephone/email contact during a 12-month period. The total time commitment is approximately 2-3 hours.
If you are enrolled in MOSAIC-1, you will not be scheduled for any more MOSIAC-1 study visits and instead have MOSIAC-2 study visits only. You do not need to have participated in MOSAIC-1 to join MOSAIC-2. If you were in MOSAIC-1 you can join MOSAIC-2.
You will also be asked to record a diary, where you will note information regarding your symptoms for the first 7 days after your vaccine, and to complete a paper questionnaire twice over the study regarding your opinion about the vaccines.
The following procedures will be done at the study visits and contacts:
• Medical History
• Vital Signs
• Demographic Information
• Blood Sample
• Pregnancy Test if indicated
Why is this study being done?
COVID-19 vaccination programs started in Canada in December 2020 with vaccines becoming available over the winter and into spring of 2021. In Canada, a strategy to deliver as many first vaccine doses as possible resulted in mixed vaccine brands (giving a different second COVID-19 vaccine to the first dose) and schedules (length of time between vaccine doses) being used in many parts of the country.
Start Date: July 2020
The initial MOSAIC study is comparing the effectiveness, safety, and acceptability of different dosing schedules of the first two doses of COVID-19 vaccines. That study began in June 2021 and is ongoing at 7 clinical sites in Canada where 195 participants were enrolled and received either both of their vaccines or the second authorized COVID-19 vaccine. Assessment is ongoing.
Start date: December 2021
In this study, we will evaluate a third (3rd) dose of an authorized COVID-19 vaccine in adults.
In this study we will evaluate the safety, tolerability, and immune response (resulting protection) of a third dose of a COVID-19 vaccine currently authorized in Canada (either the Pfizer-BioNTech or Moderna mRNA vaccine) in people who had two doses of COVID-19 vaccines at least six months ago.
The study is led by the Clinical Trials Network of the Canadian Immunization Network (CIRN) and funded by the COVID-19 Immunity Task Force. It is led by Dr. Joanne Langley and Dr. Manish Sadarangani of CTN.
Most recent public health guidance
NACI guidance on booster COVID-19 vaccine doses in Canada – Update December 3 (Government of Canada, .pdf)
Rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines (Government of Canada, .pdf)